US Pharma MarketingGOP chairman of China panel seeks biotech clampdown, calls out BMS deal
A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
A key Republican congressman asked the Trump administration to restrict the stream of money into China’s biotech sector, threatening to squelch the dealmaking that’s become big business for some US investment companies and large pharma.
...
Source: Endpoints News